DUBLIN, June 18, 2021 /PRNewswire/ — The “Antisense & RNAi Therapeutics Global Market Report 2021: COVID-19 Growth and Change to 2030” report has been added to ResearchAndMarkets.com’s offering.
This report focuses on antisense & RNAi therapeutics market which is experiencing strong growth. The report gives a guide to the antisense & RNAi therapeutics market which will be shaping and changing our lives over the next ten years and beyond, including the markets response to the challenge of the global pandemic.
Major players in the Antisense & RNAi therapeutics market are Alnylam Pharmaceuticals, Benitec Biopharma Ltd., Gene Signal, GlaxoSmithKline Plc, Ionis Pharmaceuticals, Marina Biosciences, Quark Pharmaceuticals, Sanofi S.A, Acuitas Therapeutics, and Antisense Therapeutics Ltd.
The global antisense & RNAi therapeutics market is expected to grow from $1.11 billion in 2020 to $1.2 billion in 2021 at a compound annual growth rate (CAGR) of 8.1%.
The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges.
The market is expected to reach $1.79 billion in 2025 at a CAGR of 11%.
The antisense & RNAi therapeutics market consists of sales of antisense & RNAi therapeutics products and related services by entities (organizations, sole traders and partnerships) that develop antisense & RNAi therapeutics to treat various diseases. RNA interference (RNAi)-based and RNA-based antisense oligonucleotide therapies are advanced methods used for the treatment of various respiratory diseases including chronic obstructive pulmonary disease (COPD) and asthma. In addition to this, antisense & RNAi therapeutics finds its application in curing cancer, infectious diseases, cardiovascular diseases, and genetic disorders.
The antisense & RNAi therapeutics market covered in this report is segmented by technology into RNA interference; antisense RNA. It is also segmented by route of administration into pulmonary delivery; intravenous injections; intra-dermal injections; intraperitoneal injections; topical delivery; other delivery methods and by indication into oncology; cardiovascular diseases (CVDs); respiratory disorders; neurological disorders; infectious diseases; other.
The high cost of RNA interference-based drugs is expected to act as a major restraint for the growth of the antisense & RNAi therapeutics market in the future. For instance, according to Future Medicine, the price of Onpattro is approximately $450,000 per year. Onpattro (patisaran) is the RNA interference-based drug used for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults.
Stringent regulations, long product approval process, high development cost, and a comparably small number of patients are few factors leading to the high cost of RNA interference drugs, which is expected to hinder the antisense & RNAi therapeutics’ market growth in upcoming years.
Major companies operating in the antisense & RNAi therapeutics market are undertaking strategic initiatives such as collaborations and partnerships for product innovation to sustain in the increasingly competitive market, companies are developing innovative products as well as sharing skills and expertise with other companies. While companies have long collaborated with each other as well as with academic and research institutions in this market by way of partnerships, and in or out-licensing deals.
This trend has been increasing over recent years. For instance, in August 2020, Blackstone Life Sciences, a global investment company, and Alnylam Pharmaceuticals, Inc., an RNAi therapeutics company, announced the closing of a $2 billion strategic financing collaboration to accelerate the advancement and development of RNAi therapeutics.
Under the agreement, Alnylam Pharmaceuticals, Inc. will receive $150 million from Blackstone Life Sciences for the development of vutrisiran and ALN-AGT, Alnylam’s cardiometabolic disease programs. In 2018, Biogen and Ionis announced a collaboration to develop antisense drug candidates for neurological diseases.
This collaboration utilizes Biogen’s expertise in neuroscience research and drug development and Ionis’ knowledge in RNA targeted therapies with the goal of developing a broad pipeline of investigational therapies. The two companies signed an agreement for 10 years.
Key Topics Covered:
1. Executive Summary
2. Antisense & RNAi Therapeutics Market Characteristics
3. Antisense & RNAi Therapeutics Market Trends And Strategies
4. Impact Of COVID-19 On Antisense & RNAi Therapeutics
5. Antisense & RNAi Therapeutics Market Size And Growth
5.1. Global Antisense & RNAi Therapeutics Historic Market, 2015-2020, $ Billion
5.2. Global Antisense & RNAi Therapeutics Forecast Market, 2020-2025F, 2030F, $ Billion
6. Antisense & RNAi Therapeutics Market Segmentation
6.1. Global Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
- RNA Interference
- Antisense RNA
6.2. Global Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
- Pulmonary Delivery
- Intravenous Injections
- Intra-dermal Injections
- Intraperitoneal Injections
- Topical Delivery
- Other Delivery Methods
6.3. Global Antisense & RNAi Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
- Cardiovascular Diseases (CVDs)
- Respiratory Disorders
- Neurological Disorders
- Infectious Diseases
7. Antisense & RNAi Therapeutics Market Regional And Country Analysis
7.1. Global Antisense & RNAi Therapeutics Market, Split By Region, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
7.2. Global Antisense & RNAi Therapeutics Market, Split By Country, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
- Alnylam Pharmaceuticals
- Benitec Biopharma Ltd.
- Gene Signal
- GlaxoSmithKline Plc
- Ionis Pharmaceuticals
- Marina Biosciences
- Quark Pharmaceuticals
- Sanofi S.A
- Acuitas Therapeutics
- Antisense Therapeutics Ltd.
- Arbutus Biopharma (formerly known as Tekmira Pharmaceuticals)
- Bio-Path Holdings Inc.
- Calando Pharmaceuticals
- Dicerna Pharmaceuticals
- Enzon Pharmaceuticals Inc
- iCo Therapeutics
- miRagen Therapeutics
- Olix Pharmaceuticals
- OncoGeneX Pharmaceuticals
- Lorus Therapeutics (Aptose Biosciences)
- Regulus Therapeutics
- Rexahn Pharmaceuticals
- Rxi Pharmaceuticals
- Santaris Pharma A/S (Roche)
- Sarepta Therapeutics
- Silence Therapeutics Plc
- Sirnaomics Inc.
- Tekmira Pharmaceuticals
- Cenix BioScience
For more information about this report visit https://www.researchandmarkets.com/r/3zmpgf
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets